Obecabtagene autoleucel
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Nephritis
Conditions
Lupus Nephritis
Trial Timeline
Sep 1, 2025 → Feb 1, 2030
NCT ID
NCT07053800About Obecabtagene autoleucel
Obecabtagene autoleucel is a phase 2 stage product being developed by Autolus Therapeutics for Lupus Nephritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07053800. Target conditions include Lupus Nephritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07400029 | Phase 2 | Recruiting |
| NCT07053800 | Phase 2 | Recruiting |
| NCT07053059 | Phase 2 | Recruiting |
Competing Products
20 competing products in Lupus Nephritis